Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma
Robert Fred Henry Walter,1,2 Saskia Roxanne Sydow,3 Erika Berg,3 Jens Kollmeier,4 Daniel Christian Christoph,5,6 Sandra Christoph,7 Wilfried Ernst Erich Eberhardt,1 Thomas Mairinger,4 Jeremias Wohlschlaeger,2 Kurt Werner Schmid,2 Fabian Dominik Mairinger2 1Ruhrlandklinik, West German Lung Center, Un...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-09-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/bortezomib-sensitivity-is-tissue-dependent-and-high-expression-of-the--peer-reviewed-article-CMAR |
| _version_ | 1818972566878945280 |
|---|---|
| author | Walter RFH Sydow SR Berg E Kollmeier J Christoph DC Christoph S Eberhardt WEE Mairinger T Wohlschlaeger J Schmid KW Mairinger FD |
| author_facet | Walter RFH Sydow SR Berg E Kollmeier J Christoph DC Christoph S Eberhardt WEE Mairinger T Wohlschlaeger J Schmid KW Mairinger FD |
| author_sort | Walter RFH |
| collection | DOAJ |
| description | Robert Fred Henry Walter,1,2 Saskia Roxanne Sydow,3 Erika Berg,3 Jens Kollmeier,4 Daniel Christian Christoph,5,6 Sandra Christoph,7 Wilfried Ernst Erich Eberhardt,1 Thomas Mairinger,4 Jeremias Wohlschlaeger,2 Kurt Werner Schmid,2 Fabian Dominik Mairinger2 1Ruhrlandklinik, West German Lung Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; 2Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; 3Institute of Pathology, Charité Universitaetsmedizin, Berlin, Germany; 4Institute of Pathology, Helios Klinikum Emil Von Behring, Berlin, Germany; 5Department of Oncology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; 6Department of Internistic Oncology, Kliniken Essen Mitte, Essen, Germany; 7Department of Bone Marrow Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, GermanyCorrespondence: Robert Fred Henry WalterUniversity Hospital Essenm, Institute of Pathology, Hufelandstraße 55, Essen D-45147, GermanyTel +49 0 201/723 84828Fax +49 0 201/723 3880Email robert.walter@ruhrlandklinik.uk-essen.deBackground: Bortezomib is an approved proteasome inhibitor for the treatment of certain lymphoma subtypes. Two clinical trials investigated bortezomib in patients with malignant pleural mesothelioma (MPM) and failed to improve outcome. We present a potential explanation for this event.Methods: 171 patients with MPM were analyzed for their mRNA expression of proteasomal subunits PSMA1, PSMA5, PSMB1, PSMB2, PSMB4 and PSMB5 via qPCR (n=84) or sequencing (n=87 TCGA/cBioPortal data set “Mesothelioma”). Outcome and subunit expression were correlated. Four mesothelial and one fibroblast cell line were treated with bortezomib and cisplatin. Cellular response was measured after 0, 6, 12, 24, 48 and 72 hrs. Enzyme activity of proteasomal subunits was assessed via functional enzyme activity assays.Results: Patients with MPM presented with elevated expression of proteasomal subunits compared to benign controls (p<0.001). PSMB4 correlated with outcome (Cox propotiortional-hazards model (COXPH): p<0.0175, TCGA/cBioPortal data). In cell lines, apoptosis was the main event with a peak after 48 hr incubation for bortezomib or cisplatin. Only two cell lines with comparably low proteasome activity (PSMB2 and PSMB5) responded to 50 nM and 100 nM bortezomib better than to cisplatin (MRC-5, NCI-H2052). MSTO-211H responded to cisplatin only, whereas the other two cell lines were considered therapy resistant (Met-5A, NCI-H2452).Interpretation: Two clinical trials testing bortezomib in MPM failed, although MPM presents with high proteasome expression, which predicts bortezomib sensitivity in several tumors. Bortezomib induced apoptosis in MPM cell lines with low proteasome activity only. Bortezomib is not suitable for the treatment of MPM, and biomarker-based stratification could have improved both clinical trials.Trial registration: NCT00513877 and NCT00458913Keywords: bortezomib, proteasome, malignant pleural mesothelioma, TCGA, biomarker |
| first_indexed | 2024-12-20T15:10:19Z |
| format | Article |
| id | doaj.art-132bfd3cdaea488580c1757ea6e01126 |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-12-20T15:10:19Z |
| publishDate | 2019-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-132bfd3cdaea488580c1757ea6e011262022-12-21T19:36:21ZengDove Medical PressCancer Management and Research1179-13222019-09-01Volume 118711872048790Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesotheliomaWalter RFHSydow SRBerg EKollmeier JChristoph DCChristoph SEberhardt WEEMairinger TWohlschlaeger JSchmid KWMairinger FDRobert Fred Henry Walter,1,2 Saskia Roxanne Sydow,3 Erika Berg,3 Jens Kollmeier,4 Daniel Christian Christoph,5,6 Sandra Christoph,7 Wilfried Ernst Erich Eberhardt,1 Thomas Mairinger,4 Jeremias Wohlschlaeger,2 Kurt Werner Schmid,2 Fabian Dominik Mairinger2 1Ruhrlandklinik, West German Lung Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; 2Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; 3Institute of Pathology, Charité Universitaetsmedizin, Berlin, Germany; 4Institute of Pathology, Helios Klinikum Emil Von Behring, Berlin, Germany; 5Department of Oncology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; 6Department of Internistic Oncology, Kliniken Essen Mitte, Essen, Germany; 7Department of Bone Marrow Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, GermanyCorrespondence: Robert Fred Henry WalterUniversity Hospital Essenm, Institute of Pathology, Hufelandstraße 55, Essen D-45147, GermanyTel +49 0 201/723 84828Fax +49 0 201/723 3880Email robert.walter@ruhrlandklinik.uk-essen.deBackground: Bortezomib is an approved proteasome inhibitor for the treatment of certain lymphoma subtypes. Two clinical trials investigated bortezomib in patients with malignant pleural mesothelioma (MPM) and failed to improve outcome. We present a potential explanation for this event.Methods: 171 patients with MPM were analyzed for their mRNA expression of proteasomal subunits PSMA1, PSMA5, PSMB1, PSMB2, PSMB4 and PSMB5 via qPCR (n=84) or sequencing (n=87 TCGA/cBioPortal data set “Mesothelioma”). Outcome and subunit expression were correlated. Four mesothelial and one fibroblast cell line were treated with bortezomib and cisplatin. Cellular response was measured after 0, 6, 12, 24, 48 and 72 hrs. Enzyme activity of proteasomal subunits was assessed via functional enzyme activity assays.Results: Patients with MPM presented with elevated expression of proteasomal subunits compared to benign controls (p<0.001). PSMB4 correlated with outcome (Cox propotiortional-hazards model (COXPH): p<0.0175, TCGA/cBioPortal data). In cell lines, apoptosis was the main event with a peak after 48 hr incubation for bortezomib or cisplatin. Only two cell lines with comparably low proteasome activity (PSMB2 and PSMB5) responded to 50 nM and 100 nM bortezomib better than to cisplatin (MRC-5, NCI-H2052). MSTO-211H responded to cisplatin only, whereas the other two cell lines were considered therapy resistant (Met-5A, NCI-H2452).Interpretation: Two clinical trials testing bortezomib in MPM failed, although MPM presents with high proteasome expression, which predicts bortezomib sensitivity in several tumors. Bortezomib induced apoptosis in MPM cell lines with low proteasome activity only. Bortezomib is not suitable for the treatment of MPM, and biomarker-based stratification could have improved both clinical trials.Trial registration: NCT00513877 and NCT00458913Keywords: bortezomib, proteasome, malignant pleural mesothelioma, TCGA, biomarkerhttps://www.dovepress.com/bortezomib-sensitivity-is-tissue-dependent-and-high-expression-of-the--peer-reviewed-article-CMARbortezomibproteasomemalignant pleural mesotheliomaTCGAbiomarker |
| spellingShingle | Walter RFH Sydow SR Berg E Kollmeier J Christoph DC Christoph S Eberhardt WEE Mairinger T Wohlschlaeger J Schmid KW Mairinger FD Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma Cancer Management and Research bortezomib proteasome malignant pleural mesothelioma TCGA biomarker |
| title | Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma |
| title_full | Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma |
| title_fullStr | Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma |
| title_full_unstemmed | Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma |
| title_short | Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma |
| title_sort | bortezomib sensitivity is tissue dependent and high expression of the 20s proteasome precludes good response in malignant pleural mesothelioma |
| topic | bortezomib proteasome malignant pleural mesothelioma TCGA biomarker |
| url | https://www.dovepress.com/bortezomib-sensitivity-is-tissue-dependent-and-high-expression-of-the--peer-reviewed-article-CMAR |
| work_keys_str_mv | AT walterrfh bortezomibsensitivityistissuedependentandhighexpressionofthe20sproteasomeprecludesgoodresponseinmalignantpleuralmesothelioma AT sydowsr bortezomibsensitivityistissuedependentandhighexpressionofthe20sproteasomeprecludesgoodresponseinmalignantpleuralmesothelioma AT berge bortezomibsensitivityistissuedependentandhighexpressionofthe20sproteasomeprecludesgoodresponseinmalignantpleuralmesothelioma AT kollmeierj bortezomibsensitivityistissuedependentandhighexpressionofthe20sproteasomeprecludesgoodresponseinmalignantpleuralmesothelioma AT christophdc bortezomibsensitivityistissuedependentandhighexpressionofthe20sproteasomeprecludesgoodresponseinmalignantpleuralmesothelioma AT christophs bortezomibsensitivityistissuedependentandhighexpressionofthe20sproteasomeprecludesgoodresponseinmalignantpleuralmesothelioma AT eberhardtwee bortezomibsensitivityistissuedependentandhighexpressionofthe20sproteasomeprecludesgoodresponseinmalignantpleuralmesothelioma AT mairingert bortezomibsensitivityistissuedependentandhighexpressionofthe20sproteasomeprecludesgoodresponseinmalignantpleuralmesothelioma AT wohlschlaegerj bortezomibsensitivityistissuedependentandhighexpressionofthe20sproteasomeprecludesgoodresponseinmalignantpleuralmesothelioma AT schmidkw bortezomibsensitivityistissuedependentandhighexpressionofthe20sproteasomeprecludesgoodresponseinmalignantpleuralmesothelioma AT mairingerfd bortezomibsensitivityistissuedependentandhighexpressionofthe20sproteasomeprecludesgoodresponseinmalignantpleuralmesothelioma |